Large biopharma companies cull about 40 immuno-oncology programs over the last two quarters
Clinical trial failures, patient enrollment struggles, new priorities and a transformed FDA are just a few of the reasons why some of the top biopharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
